Novel ginsenoside monomer RT4 promotes colitis repair in mice by regulating miR‐144‐3p/SLC7A11 signaling pathway

Abstract

AbstractBackgroundGinsenoside RT4 (RT4) is a new biologically active compound extracted from ginseng that possesses numerous medicinal and pharmacological properties. However, its potential therapeutic effect of ginsenoside RT4 on ulcerative colitis remains unknown.Methods and resultsIn this study, we investigated the anti‐inflammatory effects of ginsenoside RT4 and its underlying molecular mechanism in the treatment of ulcerative colitis mice induced with dextran sulfate sodium (DSS). Our results demonstrate that ginsenoside RT4 effectively reduced weight, shortening of colonic tract length, colonic bowel damage, and disease activity index (DAI) scores in DSS‐induced colitis mice. Additionally, ginsenoside RT4 regulates miR‐144‐3p expression in DSS‐induced colitis mice, and we further confirmed that the solute carrier family 7 member 11 (SLC7A11) was the target gene of miR‐144‐3p by database analysis. Finally, ginsenoside RT4 inhibits the activation of the miR‐144‐3p/SLC7A11 signaling pathway, which alleviates colitis. Ginsenoside RT4 significantly decreased the expression of pro‐inflammatory cytokines TNF‐α and IL‐1β and increased the anti‐inflammatory cytokine IL‐10.ConclusionsThese findings suggest that ginsenoside RT4 may have therapeutic potential for treating ulcerative colitis by downregulating levels of miR‐144‐3p/SLC7A11 signaling pathway, which are expected to be useful in treating clinical ulcerative colitis.